- Home
- NEWP vs CLLS Comparison
NEWP vs CLLS Comparison
Compare NEWP & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- CLLS
- Stock Information
- Founded
- NEWP 1972
- CLLS 1999
- Country
- NEWP Canada
- CLLS France
- Employees
- NEWP N/A
- CLLS N/A
- Industry
- NEWP
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- CLLS Health Care
- Exchange
- NEWP Nasdaq
- CLLS Nasdaq
- Market Cap
- NEWP 363.2M
- CLLS 299.0M
- IPO Year
- NEWP N/A
- CLLS 2007
- Fundamental
- Price
- NEWP $2.17
- CLLS $2.89
- Analyst Decision
- NEWP
- CLLS Buy
- Analyst Count
- NEWP 0
- CLLS 1
- Target Price
- NEWP N/A
- CLLS $4.00
- AVG Volume (30 Days)
- NEWP 434.0K
- CLLS 73.0K
- Earning Date
- NEWP 11-12-2025
- CLLS 11-03-2025
- Dividend Yield
- NEWP N/A
- CLLS N/A
- EPS Growth
- NEWP N/A
- CLLS N/A
- EPS
- NEWP N/A
- CLLS N/A
- Revenue
- NEWP N/A
- CLLS $63,438,000.00
- Revenue This Year
- NEWP N/A
- CLLS N/A
- Revenue Next Year
- NEWP N/A
- CLLS $66.76
- P/E Ratio
- NEWP N/A
- CLLS N/A
- Revenue Growth
- NEWP N/A
- CLLS 223.09
- 52 Week Low
- NEWP $0.93
- CLLS $1.10
- 52 Week High
- NEWP $2.17
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- NEWP 69.94
- CLLS 58.24
- Support Level
- NEWP $1.88
- CLLS $2.53
- Resistance Level
- NEWP $2.15
- CLLS $3.35
- Average True Range (ATR)
- NEWP 0.12
- CLLS 0.16
- MACD
- NEWP 0.03
- CLLS 0.01
- Stochastic Oscillator
- NEWP 99.02
- CLLS 45.88
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.